Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
Video navigation menu
- Residual risk in patients with ACS and diabetes 0:31
- Inflammatory residual risk post ACS in diabetic patients 2:13
- Apabetalone may target several residual risk factors 3:38
- Clinical trials with apabetalone 4:12
This lecture held by prof. Ray was part of an accredited symposium "Epigenetics: A new pathway to tackle residual risk?" held during ESC Congress 2019 in Paris, France.
Prof. Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: